Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects With Acute Exacerbation of Schizophrenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jun 2019
Price :
$35
*
At a glance
- Drugs Aripiprazole lauroxil (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Alkermes plc
- 19 Sep 2017 Results of post-hoc subgroup analysis from parent (EudraCT2012-003445-15) and their extension (EudraCT2012-003996-20) studies published in the Journal of Clinical Psychiatry
- 30 Aug 2016 Results published in the Journal of Clinical Psychiatry (2016).
- 28 Mar 2016 Data from this trial will be presented at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference 2016, according to an Alkermes plc media release.